Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years
- 1 June 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 75 (12), 2048-2053
- https://doi.org/10.1097/01.tp.0000069831.76067.22
Abstract
Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus (TAC) + mycophenolate mofetil (MMF), TAC + azathioprine (AZA), or cyclosporine (Neoral; CsA) + MMF. All regimens contained corticosteroids, and antibody induction was used only in patients who experienced delayed graft function (DGF). Patients were followed-up for 3 years. The results at 3 years corroborate and extend the findings of the 2-year results. Patients with DGF treated with TAC+MMF experienced an increase in 3-year allograft survival compared with patients receiving CsA+MMF (84.1% vs. 49.9%, P=0.02). Patients randomized to either treatment arm containing TAC exhibited numerically superior kidney function when compared with CsA. During the 3 years, new-onset insulin dependence occurred in 6, 3, and 11 patients in the TAC+MMF, CsA+MMF, and TAC+AZA treatment arms, respectively. Furthermore, patients randomized to TAC+MMF received significantly lower doses of MMF as compared with those who received CsA+MMF. All three immunosuppressive regimens provided excellent safety and efficacy. However, the best results overall were achieved with TAC+MMF. The combination may provide particular benefit to kidney allograft recipients with DGF. In patients who experienced DGF, graft survival was better at 3 years in those patients receiving TAC in combination with either MMF or AZA as compared with the patients receiving CsA with MMF.Keywords
This publication has 12 references indexed in Scilit:
- Effect of Cyclosporine on Mycophenolic Acid Area Under the Concentration–Time Curve in Pediatric Kidney Transplant RecipientsTherapeutic Drug Monitoring, 2001
- RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS1Transplantation, 2001
- Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic AcidTherapeutic Drug Monitoring, 2001
- RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2Transplantation, 2000
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Delayed graft function: risk factors and the relative effects of early function and acute rejection on long‐term survival in cadaveric renal transplantationClinical Transplantation, 1999
- DELAYED GRAFT FUNCTION AFTER RENAL TRANSPLANTATION1Transplantation, 1998
- DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1Transplantation, 1997
- The relative influence of delayed graft function and acute rejection on renal transplant survivalTransplant International, 1996
- DELAYED GRAFT FUNCTION, ACUTE REJECTION, AND OUTCOME AFTER CADAVER RENAL TRANSPLANTATIONTransplantation, 1995